

# EBUS INDICATIONS


## CASE DISCUSSION



Ersin GÜNAY, MD  
Ankara Etlik City Hospital


# Contents

- ◆ Types of EBUS (Radial Probe & Convex Probe)
- ◆ Lymph node stations (could be sampled via EBUS)
- ◆ EBUS indications (case samples)
- ◆ Disadvantages and Complications
- ◆ Future tech for EBUS



### Conventional TBNA (Wang TBNA)

Sensitivity: 78%,  
Specificity: 100%



### EBUS TBNA

Sensitivity: 89%  
Specificity: 100%



*CHEST 2013; 143(5)(Suppl):e211S-e250S*

# Types of EBUS

## RADIAL PROBE EBUS




## CONVEX PROBE EBUS



# Endobronchial Ultrasound (EBUS)

## 1-Radial probe EBUS (rp-EBUS) (Miniprobe) (early 1990's)

- ◇ 2 mm (ultraminiature) or 2.8 mm (miniature) US prob (used through FOB)
- ◇ 360° ultrasound view angle
  - Visualization of peripheral mass/nodules, and lymph nodes
  - Guidance for TBNA/biopsy (via catheter guide)
  - Differentiation vascular lesions from nonvascular
  - Evaluation for tumoral invasion (early tumoral stage)
  - Guidance for endobronchial treatment options




# Endobronchial Ultrasound (EBUS)

## 2- Konveks Prob-EBUS (cp-EBUS)- TBIA

- ◇ Produced in 2000's.
- ◇ Minimally invasive
- ◇ Hibrid device used for
  - ◇ Visualization for lesions located mediastinal and hilar region
  - ◇ Sampling (simultaneously)
- ◇ Doppler feature

- Lymph Nodes
- Mass lesions
- Main vasculature



Yasufuki K, Oncol Rep 2004;11:293-6.  
Yasufuki K, Chest 2004;126:122-8.

# rp-EBUS vs cp-EBUS

## Features

rp-EBUS



cp-EBUS



View angle

360°

80-120°

Penetration

4-5 cm

>5 cm

Resolution

Relatively worse

Better

Color Doppler

Not present

Present

Real Time Sampling

Not present

Present

Elastography

Not present

Present

AGE:  
DOB: SEX:  
31/05/2016  
10:25:56  
1DHz 4cm  
G:16/19 I:L2  
C:4/8 FC:3  
L.DEN:x2.0  
TX:100X  
MEDIA  
T/R:MEAS.OIS  
1/160  
+: 27.4mm




DIR:  
NOR  
SCL:  
5mm





OLYMPUS







# MEDIASTINAL LYMPH NODES




IASLC



The International Association for the Study of Lung Cancer (IASLC)

# Lymph Node Map



## Superior Mediastinal Nodes

- 1 Highest Mediastinal
- 2 Upper Paratracheal
- 3 Pre-vascular and Retrotracheal
- 4 Lower Paratracheal (including Azygos Nodes)

N<sub>2</sub> = single digit, ipsilateral  
N<sub>2</sub> = single digit, contralateral or supraclavicular

Upper zone (R)

## Aortic Nodes

- 5 Subaortic (A-P window)
- 6 Para-aortic (ascending aorta or phrenic)

AP zone (L)

## Inferior Mediastinal Nodes

- 7 Subcarinal
- 8 Paraesophageal (below carina)
- 9 Pulmonary Ligament

Subcarinal zone


Lower zone


## N<sub>1</sub> Nodes

- 10 Hilar
- 11 Interlobar
- 12 Lobar
- 13 Segmental
- 14 Subsegmental

Hilar zone

Peripheral zone





- EBUS-TBNA and Mediastinoscopy
- EBUS-TBNA
- EUS-FNA

# cp-EBUS Indications

- ◇ Staging/Diagnosis
  - ◇ NSCLC / Extrapulmonary tumors with mediastinal metastasis
  - ◇ Restaging

# Mediastinal Staging

## Non-invasive Methods:

CT



PET-CT



## Invasive Methods:

Needle biopsies

Surgical:  
Mediastinoscopy, VAM, VATS

Minimally Invasive:  
cTBNA (Wang), EBUS, EUS, Tru-cut Bx

If a cancer patient is a candidate for surgery

HISTOPATHOLOGICAL SAMPLING

of mediastinal lymph nodes

is essential


FOR STAGING.


Cancer 1992; 70: 1102

Ann Thorac Surg 1991; 51: 253

Am J Respir Crit Care Med 1997; 156: 320

# NSCLC MEDIASTINAL INVASIVE STAGING



 **CHEST** Supplement  
DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES

**Methods for Staging Non-small Cell Lung Cancer**

Diagnosis and Management of Lung Cancer,  
3rd ed: American College of Chest Physicians  
Evidence-Based Clinical Practice Guidelines






EBUS

WHEN?

WHICH CASES?



- ◆ In cases where the tumor has caused extensive mediastinal infiltration and there is no distant metastasis
  - ◆ For mediastinal staging, evaluation with CT is usually sufficient without the need for invasive confirmation.
- (Grade 2C)



- ◆ In cases with significant mediastinal lymph node enlargement (and no distant metastasis),
  - ◆ Invasive staging of the mediastinum is recommended for mediastinal lymph nodes, regardless of whether there is PET uptake.


(Grade 1C)



◇ For mediastinal lymph nodes that show activity on PET-CT but appear normal on CT (and without distant metastasis)

◇ Invasive mediastinal staging should be preferred over imaging alone.

(Grade 1C)



- ◇ Central tumor or enlarged N1 lymph node,
- ◇ The mediastinum is normal (based on CT and PET scan findings),
- ◇ No distant metastases,
- ◇ N2 or N3 involvement is moderately suspicious,
- ◇ Invasive mediastinal staging should be performed.

(Grade 1C)

- In this patient group, it is recommended to prefer needle techniques (such as EBUS-TBNA, EUS-FNA, or combined EBUS/EUS-FNA) as the best initial test for surgical staging (Grade 2B).
- If staging with needle techniques is negative but clinical suspicion remains high, surgical staging should be performed.

# CT and PET CT

Mediastinum LNs Negative

- cN0
- Peripheral Tumour (outer third of lung)
- Tumour  $\leq 3$ cm

- cN1 and
- Central Tumour (outer third of lung)
- Tumour  $>3$ cm (esp. Adneocarcinoma)

Tissue confirmation:  
EBUS/EUS  
or  
VAM

Mediastinum LN's Positive

Tissue confirmation:  
EBUS/EUS

Negative LNs

Positive LNs

Negative LNs


VAM

Multimodality Treatment

Positive LNs

Negative LNs

Surgery



# cp-EBUS Indications

## ◇ Staging

- ◇ NSCLC / Extrapulmonary tumors with mediastinal metastasis
- ◇ Restaging


- >5mm and at least 3 different lymph node stations are suggested to be sampled
  - **N3→N2→N1**
- «Cortex to cortex» aspiration
- Move the needle back and forth inside 15-20 times through the LNs
- How many time puncturing is enough for a lymph node st.
  - At least 3 times sampling (sens.:%95,sps.:%100) for diagnosis
  - At least 4 times for molecular analysis (mutations)





# CASE 1

- 42 yoa, ♂
- Dry cough, dyspnea
- Smoker (20 pack-years)
- Right hilar mass



**FOB:** Totally obliterating necrotizing endobronchial lesion at middle lobe orifice.


**Pathology:**

«ADENOCARCINOMA»



# FDG PET-CT

- Right hilar mass at the level of middle lobe (2.5x3 cm in diameter) (SUVmax:6.75)
- In mediastinum;
  - Left lower paratracheal (SUVmax:4.64),
  - Paraaortic (SUVmax:5.10),
  - Aorticopulmonary (SUVmax:4.15),
  - Subcarinal (SUVmax:4.10),
  - Paraesophageal (SUVmax:4.94),
  - Right hilar (SUVmax:4.12)



**4L:** 11.2 mm, distinct margin, heterogenous, hypoechogenic, round shaped

**7:** 19.2 mm, distinct margin, heterogenous, hypoechogenic, round shaped

**11R:** 13.9 mm, distinct margin, heterogenous, hypoechogenic, round shaped and central necrosis



## EBUS PATHOLOGY

Metastatic Lymph Nodes (4L, 7 & 11R)

cT1c pN3 M0 Stage-3B


Molecular Investigation:

ALK, EGFR, K-RAS and ROS (Negative)

# CASE 2

- 52 yoa, ♂
- Coughing with sputum
- No haemoptysis
- 35 pack-years
- Asbest exposure (+)






## Bronchoscopy:

Normal

## Tru-cut bx:



In the examined sections, there are areas of fibrotic and hyalinized tissue infiltrated with dense mononuclear inflammatory cells. A few large, hyperchromatic nuclei are observed at the edges of these tissues..


IHC: pansitokeratin (+), P63 (+), TTF-1 (-)

*\*Due to the reduction in these areas on serial sections, further interpretation for diagnosis could not be performed.*



## FDG PET-CT

- ✓ 44x45x40 mm in diameter mass lesion on right lower lobe (SUVmax:16.38)
- ✓ Right hilar (SUVmax:4.96) and subcarinal (SUVmax:4.41) metabolically active lymph nodes



# EBUS

**11L:** 9.9 mm, distinct margin, heterogenous, hypoechogenic, oval shaped

**7:** 17.2 mm, irregular border, heterogenous, hypoechogenic, round shaped

**11R:** 14.4 mm distinct margin, heterogenous, hypoechogenic, oval shaped

## PATHOLOGY

All lymph nodes exhibit **antracotic feature**



# PATHOLOGY for SURGICAL SAMPLING

Tanı

- SKUAMÖZ HÜCRELİ KARSİNOMA / ORTA DERECEDE DİFERANSİYE; sağ alt lobektomi
- METASTATİK LENF NODLARI, 1 adet peribronşial
- REAKTİF ANTRAKOTİK LENF NODLARI, 2 - 4 - 7 - 8 ve 9 nolu
- Sağ torakotomi

NOT:

- Bronş cerrahi sınırında tümör yoktur.
- Plevral tutulum yoktur.
- 10 nolu lenf nodu kayıtlı dokuda lenf nodu yapısı yoktur. Bu örnekler tümör içermeyen akciğer parankiminden oluşmaktadır.
- Tümörün büyük çapı 5,5 cm7dir.
- Tümör dışı akciğer parankiminde kalsifiye nodüler lezyonlar izlenmektedir.

Squamous Cell Carcinoma with metastatic peribronchial lymph node.

pT3 pN1 M0 → Stage IIIA

# cp-EBUS Indications

- ◇ Staging/Diagnosis
  - ◇ NSCLC / Extrapulmonary tumors with mediastinal metastasis
  - ◇ Restaging




## • Pulmonar Embolism

(embolism in main pulmonary artery)

- Contraindication for contrast media
- Pregnancy
- Patients followed in ICU
- Diagnostic accuracy 96%

(lower diagnostic accuracy for lower and middle pulmonary artery)





# cp-EBUS Indications

- ◇ Staging/Diagnosis
  - ◇ NSCLC / Extrapulmonary tumors with mediastinal metastasis
  - ◇ Restaging
- ◇ Pulmonar Embolism
  
- Non-thrombotic endovascular lesions (NELs)
  - Pulmonary hydatid cyst embolism
  - Pulmonary arterial sarcoma,
  - Pulmonary arterial aneurysm
  - Tumors of the vena cava

# Case 3

- ◇ 30 years old female
- ◇ Cough (very rare)
- ◇ Treated 14 days for pneumonia
- ◇ No smoking
- ◇ Housewife (not working)
- ◇ No medical history
- ◇ Control chest X-ray (14th day of treatment)







◆ Thorax CT

Right paratracheal lymph node (20X15 mm)

◆ PET-CT:

4R , SUVmax: 8.7






◆ EBUS performed



TEXT  
1:LN  
2:T  
3:Ao  
4:IVC  
5:Panc  
6:CBD  
7:PA  
8:SVC

OLYMPUS

DIR:  
NOR



Strongly (+) with Vimentin and CD34  
Ki67 proliferation index is 5 %  
«**Epithelioid Hemangioendothelioma**»





## Case 4

- ◇ 45 year old male
- ◇ Productive cough for 2 weeks
- ◇ Chst X-ray: Right hilar enlargement



2018  
01/2018  
57:48







am  
01/2018  
57:36



- ◇ **Bronchoscopy:**

Enlargement at the level of main carina and visible pulsation



Günay E, Kaya F, Günay S. Tuberk Toraks. 2018 ;66(3):268-270.



# cp-EBUS Indications

- ◇ Staging/Diagnosis
  - ◇ NSCLC / Extrapulmonary tumors with mediastinal metastasis
  - ◇ Restaging
- ◇ Pulmonar Embolism
- ◇ Non-thrombotic endovascular lesions (NELs)
- ◇ **Thyroid nodule needle aspiration (substernal localization)**

# cp-EBUS Indications

- ◇ Staging/Diagnosis
  - ◇ NSCLC / Extrapulmonary tumors with mediastinal metastasis
  - ◇ Restaging
- ◇ Pulmonar Embolism
- ◇ Non-thrombotic endovascular lesions (NELs)
- ◇ Thyroid nodule needle aspiration (substernal localization)



## • Therapeutic applications

- Drainage (Mediastinal cyst, abscess and lymphangioma)
- Transbronchial needle injection (TBNI)

# cp-EBUS Indications

- ◇ Staging/Diagnosis
  - ◇ NSCLC / Extrapulmonary tumors with mediastinal metastasis
  - ◇ Restaging
  - ◇ Pulmonary Embolism



- Cardiac indications
  - Aspiration for pericardial effusion
  - Diagnosis of atrial mass lesions (Cardiac tumors)



# cp-EBUS Indications

- ◇ Staging/Diagnosis
  - ◇ NSCLC / Extrapulmonary tumors with mediastinal metastasis
  - ◇ Restaging
- ◇ Pulmonar Embolism
- ◇ Non-thrombotic endovascular lesions (NELs)
- ◇ Thyroid nodule needle aspiration (substernal localization)
- ◇ Therapeutic applications,
- ◇ Cardiac indications
- ❖ Diagnosis of other mediastinal lesions
  - ❖ Lymphoma
  - ❖ Granulomatous diseases
    - ❖ Sarcoidosis
    - ❖ Tuberculosis


## Case 5

- ◇ 75 yoa, Male
- ◇ Back pain for 3 months
- ◇ Cough with phlegm
- ◇ Dyspnea
- ◇ Weight loss (6 kg per/ 3 months)
- ◇ Night sweating
- ◇ No fever



# Case 5

## Medical History

- ◆ Smoking (+)
  - ◆ ex-smoker; 25 pack-years
- ◆ Farmer
- ◆ CAD (+) (angiography, balloon tx)
- ◆ Hyperlipidemia (+)








# PET CT

- ◆ Extensive mediastinal lymphadenopathy, with the largest lymph node measuring 1.5 x 1.5 cm ( $SUV_{max}$ : 7.47).



# EBUS



◇ 4R and 4L; 9 mm, heterogenous, partial blue

◇ 7; 23 mm, partial blue

◇ 11R; 17 mm and partial blue

◇ 11L; 17 mm heterogenous, round

◇ 11L → 4L → 7 → 4R → 11R



# PATHOLOGY


- ◆ All sampled lymph node stations revealed;
  - ◆ Diffuse positive CD20, CD5, Bcl-2 and Bcl-1
  - ◆ CD-21 reveals immune reaction representing FDRC (+) (follicular dendritic reticulum cells- Reed Sternberg cells)
  - ◆ Ki-67 proliferation index 20-25%,

FINAL DIAGNOSIS:



**MANTLE CELL LYMPHOMA**


## Case 6

- ◇ 46 years old
- ◇ Female
- ◇ No pulmonary symptom
- ◇ Mastectomized 2 years before for breast cancer
- ◇ Mediastinal pathological lymph nodes during follow-up














## PATHOLOGY

- ◆ Noncaseating granuloma, THYROID, 4R, 7, 11R,
- ◆ EZN (-) for all specimens





# cp-EBUS Indications

- ◇ Staging/Diagnosis
  - ◇ NSCLC / Extrapulmonary tumors with mediastinal metastasis
  - ◇ Restaging
- ◇ Pulmonar Embolism
- ◇ Non-thrombotic endovascular lesions (NELs)
- ◇ Thyroid Needle aspiration (substernal localization)
- ◇ Therapeutic applications,
- ◇ Cardiac indications
- ◇ Diagnosis of other mediastinal lesions

## ❖ EBUS-Mediastinal cryobiopsy

- Negative EBUS-TBNA
- Suspicion for lymphoma



# Disadvantages

- Require an supervised training period
  - 50 case with supervised practical training (ACCP)
  - At least 5-10 case / year
- Station 5,6,8 and 9 could not be sampled
- Standard fiberoptic/video bronchoscopy is required for whole airway examination and biopsies if needed.

Ernst A. , Chest 2003; 123: 1693-1717

# Contraindications



## Absolute

Absence of signed informed consent

Severe/uncontrolled bleeding diathesis

Unstable arrhythmia

Acute MI within the past 4 weeks

Supraglottic/glottic stenosis

(benign/malignant)

## Relative

Refractory hypoxemia (under 6lt/min nasal oxygen;  
SO<sub>2</sub><90%, PaO<sub>2</sub> <60 mmHg)  
(EUS-B FNA may be alternative)


Severe hypertension  
(Systolic >180, diastolic >110 mmHg)

Airway narrowing with a lumen wide enough to  
permit the passage of a bronchoscope.  
(EUS-B FNA may be alternative)

# Complications

- ◇ Most complications described as 'case reports'
- ◇ No death was reported
- ◇ 0.07% complication rate reported in a meta-analysis with 1299 patients
- ◇ 0.016% complication rate in a study with 3123 cases

**TABLE 5** Complication rates following EBUS bronchoscopy.

Complication	Performance target: Rate of complication	Reference
Hospitalization	<1%	
Bleeding		
Grade 1–2	<2%	
Grade 3–4	<1%	
Pneumothorax		
Linear EBUS	<1%	
Radial EBUS	<3%	
Pneumomediastinum	<1%	
Respiratory failure	<1%	

## Other Complications

- ◇ Pericarditis,
- ◇ Mediastinal infections
- ◇ Vocal cord injury
- ◇ Hemapneumomediastinum
- ◇ Ultramural hematoma (p. artery)

# What does the future hold for EBUS technology?

## ◇ Pulmonary Hypertension


### ◇ Diagnosis

### ◇ Follow-up

### Endobronchial ultrasound: A novel screening test for pulmonary hypertension prior to major pulmonary surgery


Check for updates

Nathaniel Deboever, MD, MSc,<sup>a</sup> George A. Eapen, MD,<sup>b</sup> Roberto F. Casal, MD,<sup>b</sup> Jean-Bernard Durand, MD,<sup>c</sup> Michael A. Eisenberg, MD,<sup>a</sup> Hope Feldman, MD, MSc,<sup>a</sup> Celestino May, MD, MAEd,<sup>a</sup> Zohra Ali, APRN, MSc,<sup>a</sup> David C. Rice, MB, BCh,<sup>a</sup> and Reza J. Mehran, MDCM, MSc<sup>a</sup>



# What does the future hold for EBUS technology?

- ◇ Pulmonary Hypertension
- ◇ 3D- 4D technology in EBUS



2D



3D



4D



HD





# What does the future hold for EBUS technology?

- ◇ Pulmonary Hypertension
- ◇ 3D-4D technology in EBUS
- ◇ High resolution- ultrathin convex EBUS probes



# What does the future hold for EBUS technology?

- ◇ Pulmonary Hypertension
- ◇ 3D-4D technology in EBUS
- ◇ High resolution- ultrathin convex EBUS probes
- ◇ Tissue Harmonic Contrast Imaging (HCI)
  - ◇ Comparing necrotic vs normal perfusion
  - ◇ Determination of the correct sampling site



# What does the future hold for EBUS technology?

- ◇ Pulmonary Hypertension
- ◇ 3D-4D technology in EBUS
- ◇ High resolution- ultrathin convex EBUS probes
- ◇ Tissue Harmonic Contrast Imaging (HCI)
- ◇ AI assisted EBUS-TBNA and robotic bronchoscopy

# What does the future hold for EBUS technology?

- ◇ Pulmonary Hypertension
- ◇ 3D-4D technology in EBUS
- ◇ High resolution- ultrathin convex EBUS probes
- ◇ Tissue Harmonic Contrast Imaging (HCI)
- ◇ AI assisted EBUS-TBNA and robotic bronchoscopy
- ◇ Disposable/Single Use EBUS



*Tbilisi*

# LUNG HEALTH CONFERENCE 2024

**18-20 OCTOBER**

**Hotels & Preference Hualing Tbilisi**



*Thank you for listening...*



Tbilisi

# LUNG HEALTH CONFERENCE 2024

18-20 OCTOBER

Hotels & Preference Hualing Tbilisi




With International Participation

# LUNG HEALTH CONGRESS

9-12 April 2025  
Sueno Deluxe Hotel,  
Belek, Antalya/Türkiye

*Your Voice, Your Congress...*

## LHC 2025



[asyoduask2025.com](http://asyoduask2025.com)



Organization Secretariat

OCT Turizm ve Seyahat Acentesi Ltd. Şti.  
19 Mayıs Mah. Büyükdere Caddesi Balçık Tarlası Sok. Tanıtı Hanı No: 1 Kat: 2 Şişli/İstanbul  
Tel: +90 212 291 15 05 • +90 541 620 20 99 • [info@asyoduask2025.com](mailto:info@asyoduask2025.com)